Seroepidemiology of hepatitis B virus infection among adults in Singapore: A 12-year review

Vaccine

Volumn 32, Issue 1, 2013, Pages 103-110

  Ang, Li Wei ^a   Cutter, Jeffery ^a   James, Lyn ^a   Goh, Kee Tai ^a,b  

^a MINISTRY OF HEALTH   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hepatitis B virus markers; Immunisation; National seroprevalence survey

Indexed keywords

HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHILDHOOD; ETHNIC GROUP; FEMALE; HEALTH CARE PLANNING; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNITY; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEROPREVALENCE; SINGAPORE; VIRUS DETECTION;

HEPATITIS B VIRUS MARKERS; IMMUNISATION; NATIONAL SEROPREVALENCE SURVEY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HISTORY, 21ST CENTURY; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PUBLIC HEALTH SURVEILLANCE; SEROEPIDEMIOLOGIC STUDIES; SINGAPORE; YOUNG ADULT;

EID: 84891926517     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.057     Document Type: Article

References (50)

1. Kao J.H., Chen D.S. Global control of hepatitis B virus infection. Lancet Infect Dis 2002, 2:395-403.
2. World Health Organization Fact sheet: Hepatitis B (updated July 2012) 2012, Available at: http://www.who.int/mediacentre/factsheets/fs204/en/index.html (accessed 09.10.12).
3. World Health Organization Western Pacific Regional Office Western Pacific Regional Plan for Hepatitis B Control Through Immunization 2007, December 2007. Available at: http://www.wpro.who.int/NR/rdonlyres/CEDD5D4E-71BE-49F4-AEEC-1384751598EE/0/POA_HepB.pdf (assessed 22.08.11).
4. Nelson C.B. Global and regional estimates of HBV-related disease burden. World Health Organization Regional Office for the Western Pacific's Working Group Meeting on Viral Hepatitis B 2002.
5. Chan S.H., Tan K.L., Goh K.T., Lim C., Tsakok M., Oon C.J., et al. Maternal-child hepatitis B virus transmission in Singapore. Int J Epidemiol 1985, 14:173-177.
6. Goh K.T., Doraisingham S., Tan K.L., Oon C.J., Ho M.L., Chen A.J., et al. The hepatitis B immunization programme in Singapore. Bull World Health Organ 1989, 67:65-70.
7. Ang L.W., Tey S.H., Cutter J., James L., Goh K.T. Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010. J Med Virol 2013, 85:583-588.
8. World Health Organization Western Pacific Region News Release 2012, Date of issue: 27 September. Western Pacific Region nearing 2012 milestone in hepatitis B control. Available at: http://www.wpro.who.int/mediacentre/releases/2012/20120927d/en/index.html (accessed 04.11.12).
9. James L., Fong C.W., Foong B.H., Wee M.K., Chow A., Shum E., et al. Hepatitis B seroprevalence study 1999. Singapore Med J 2001, 42:420-424.
10. Hong W.W., Ang L.W., Cutter J., James L., Chew S.K., Goh K.T. Changing seroprevalence of hepatitis B virus markers of adults in Singapore. Ann Acad Med Singapore 2010, 39:591-598.
11. Ministry of Health, Singapore National Health Survey 1998 1999, Ministry of Health, Singapore.
12. Ministry of Health, Singapore National Health Survey 2004 2005, Ministry of Health, Singapore.
13. Ministry of Health, Singapore National Health Survey 2010 2011, Ministry of Health, Singapore.
14. United States Centers for Disease Control and Prevention (CDC) Interpretation of hepatitis B serologic test results 2013, Available at: http://www.cdc.gov/hepatitis/hbv/pdfs/serologicchartv8.pdf (accessed 27.09.13).
15. Armitage P., Berry G., Matthews J.N.S. Statistical methods in medical research 2002, 662-663. Blackwell Science, Oxford. 4th ed.
16. Ang L.W. Seroprevalence of hepatitis B virus infection in adults in Singapore. Singapore Epidemiol News Bull 2009, 35:10-14.
17. Goh K.T. Prevention and control of hepatitis B virus infection in Singapore. Ann Acad Med Singapore 1997, 26:761-781.
18. Gust I.D. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996, 38(Suppl. 2):S18-S23.
19. World Health Organization Global alert and response (GAR)-Hepatitis B 2013, Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index4.html (accessed 27.02.13).
20. O'Sullivan B.G., Gidding H.F., Law M., Kaldor J.M., Gilbert G.L., Dore G.J. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004, 28:212-216.
21. Park S.H. Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population. Int J Infect Dis 2012, 16:e669-e672.
22. Liang X., Bi S., Yang W., Wang L., Cui G., Cui F., et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27:6550-6557.
23. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., You S.L., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007, 132:1287-1293.
24. Wasley A., Kruszon-Moran D., Kuhnert W., Simard E.P., Finelli L., McQuillan G., et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010, 202:192-201.
25. Weinbaum C.M., Williams I., Mast E.E., Wang S.A., Finelli L., Wasley A., et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008, 57(RR-8):1-20.
26. National Hepatitis B Virus (HBV) Testing Policy Expert Reference Committee, Australia National Hepatitis B Testing Policy 2012, Available at: http://www.nrl.gov.au/CA25782200833499/Lookup/Resources%20%26%20Guidelines/$file/HBV_TESTING_POLICY_FORMATTED_V1.1_PRINT.pdf (accessed 06.05.13).
27. Ministry of Health, Singapore Clinical Practice Guidelines -Chronic Hepatitis B Infection (MOH Clinical Practice Guidelines 2/2011) 2011, Ministry of Health, Singapore, Available at: http://www.moh.gov.sg/content/moh_web/healthprofessionalsportal/doctors/guidelines/cpg_medical/2011/cpgmed_chronic_hepb_infection_review.html (accessed 06.05.13).
28. Lin H.H., Wang L.Y., Hu C.T., Huang S.C., Huang L.C., Lin S.S., et al. Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan. J Med Virol 2003, 69:471-474.
29. Heng B.H., Goh K.T., Chan R., Chew S.K., Doraisingham S., Quek G.H. Prevalence of hepatitis B virus (HBV) infection in Singapore men with sexually transmitted diseases and HIV infection: role of sexual transmission in a city state with HBV intermediate endemicity. J Epidemiol Community Health 1995, 49:309-313.
30. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.
31. Chang M.H., Chen T.H., Hsu H.M., Wu T.C., Kong M.S., Liang D.C., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005, 11:7953-7957.
32. Chiang C.J., Yang Y.W., You S.L., Lai M.S., Chen C.J. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013, 310:974-976. 10.1001/jama.2013.276701.
33. Ong S.C., Lim S.G., Li S.C. How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore. Viral Hepat 2009, 16:53-63.
34. Yang B.M., Paik S.W., Hahn O.S., Yi D.H., Choi M.S., Payne S. Economic evaluation of the societal costs of hepatitis B in South Korea. J Gastroenterol Hepatol 2001, 16:301-308.
35. Jilg W., Schmidt M., Deinhardt F. Persistence of specific antibodies after hepatitis B vaccination. J Hepatol 1988, 6:201-207.
36. Jilg W., Schmidt M., Deinhardt F. Four-year experience with a recombinant hepatitis B vaccine. Infection 1989, 17:70-76.
37. Mast E.E., Margolis H.S., Fiore A.E., Brink E.W., Goldstein S.T., Wang S.A., et al. Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents 2007, MMWR Recomm Rep 2005;54:1-31. Erratum in: MMWR Morb Mortal Wkly Rep 2006;55:158-9. MMWR Morb Mortal Wkly Rep 2007;56:1267.
38. Goh K.T., Oon C.J., Heng B.H., Lim G.K. Long-term immunogenicity and efficacy of a reduced dose of plasma-based hepatitis B vaccine in young adults. Bull World Health Organ 1995, 73:523-527.
39. Tan K.L., Goh K.T., Oon C.J., Chan S.H. Immunogenicity of recombinant yeast-derived hepatitis B vaccine in non-responders to perinatal immunization. JAMA 1994, 271:859-861.
40. European Consensus Group on hepatitis B immunity Are booster immunizations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
41. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23:4158-4166.
42. Leuridan E., Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011, 53:68-75.
43. Yap E.H., Ong Y.W., Simons M.J., Okochi K., Mayumi M., Nishioka K. Australia antigen in Singapore II: differential frequency in Chinese, Malays and Indians. Vox Sang 1972, 22:371-375.
44. Simons M., Yu M., Shanmugaratnam K. Hepatitis B antigenaemia, specific immune deficiency and heptatocellualr carcinoma. Tumour Res 1973, 8:120-126.
45. Hsu L.C., Lin S.R., Hsu H.M., Chao W.H., Hsieh J.T., Wang M.C., et al. Ethnic differences in immune responses to hepatitis B vaccine. Am J Epidemiol 1996, 143:718-724.
46. Wang L.Y., Lin H.H. Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination. J Hepatol 2007, 46:1018-1025.
47. Chen Y., Wu W., Li L.J., Lou B., Zhang J., Fan J. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clin Chim Acta 2006, 372:129-133.
48. Huzly D., Schenk T., Jilg W., Neumann-Haefelin D. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008, 46:1298-1306. 10.1128/JCM.02430-07.
49. O'Brien J. Hepatitis B surface antigen: decreased need for confirmation of reactive results. Clin Chem 2000, 46:582.
50. Ni Y.H., Chang M.H., Huang L.M., Chen H.L., Hsu H.Y., Chiu T.Y., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med. 2001, 135:796-800.